secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001437749-23-031291
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen reports Q2 net loss $6.6M; fasedienol PALISADE-2 positive; cash $37.6M + $93.5M offering
--------------------------------------------------------------------------------

- Net loss $6.6M for Q2 end Sep 30, 2023 vs $17.5M YoY; R&D expense decreased to $3.9M.
- Cash $37.6M at Sep 30; raised $93.5M net from public offering plus $1.5M from Fuji Pharma.
- Fasedienol PALISADE-2 Phase 3 met primary and secondary endpoints; PALISADE-3 and -4 planned 2024; NDA target 1H 2026.
- Itruvone Phase 2B for MDD and PH80 Phase 2B for hot flashes expected 2H 2024; PH80 positive Phase 2A in PMDD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923031291/0001437749-23-031291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923031291/vtgn20231109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer